Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer
October 24, 2019 08:15 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first...
Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss
October 22, 2019 08:15 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric...
Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement
October 03, 2019 09:00 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved...
Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center
September 03, 2019 09:00 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved...
Obalon Therapeutics Inc. Announces Closing of $16.6 Million Public Offering
August 06, 2019 16:01 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”), a vertically integrated medical technology company with the first and only FDA-approved...
Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
August 05, 2019 09:00 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering
August 02, 2019 08:48 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”), a vertically integrated medical technology company with the first and only FDA-approved...
Obalon Announces Reverse Stock Split Effective Today
July 24, 2019 08:53 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Announces Second Quarter 2019 Financial Results
July 24, 2019 07:45 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Enters Into Commercial Lease for its First Company-Owned Retail Weight Loss Center
July 23, 2019 08:30 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...